Skip to main content
Equibles
BLGO logo

BLGO · Biolargo, Inc. · Metrics

Track BLGO — free

Use BLGO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BLGO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.07 0.00 (-4.93%) At close · Oct 19
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The foregoing factors raise substantial doubt about our ability to continue as a going concern, unless we are able to increase revenues, generate cash from operations, and/or generate cash from financing activities.”
View the 10-Q filed Aug 14, 2026
Market Cap
$22.35M
Shares
328.73M
Volume · Oct 19 129.99K Avg daily vol (3M) 403.11K

BLGO metrics

68 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.07
Market cap
$22.35M

Price action

20 metrics
Price change (1W)
-15.6%
Price change (30D)
-26.6%
Price change (3M)
-38.6%
Price change (6M)
-55.0%
Price change (YTD)
-62.5%
Price change (1Y)
-60.3%
Trailing year
Price change (5Y)
-62.5%
52-week high
$0.20
52-week low
$0.07
Change from 52-week high
-66.3%
Change from 52-week low
+0.0%
Annualized volatility
88.1%
Annualized volatility (3M)
85.3%
Beta
-0.1
RSI (14D)
30.8
Price vs SMA 50
-25.9%
Price vs SMA 200
-49.4%
Avg volume (3M)
403,113
Relative volume
0.3
Average dollar volume
$37,880

Company

3 metrics
Sector
Basic Materials
Industry
Specialty Chemicals
Shares outstanding
328.73M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
5.0×
reciprocal yield 20.0%
EV / EBITDA
—
EV / EBIT
—
P / sales
5.4×
reciprocal yield 18.4%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-84.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
5.5×
reciprocal yield 18.1%
EV / revenue historical average (5Y)
9.0×
reciprocal yield 11.2%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
39.9%
Operating margin
-444.0%
Trailing 12 months
Net margin
-460.3%
Gross profit (TTM)
$1.63M
Operating profit (TTM)
−$18.12M
Net income (TTM)
−$18.79M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.02

Growth

11 metrics
Revenue growth YoY
-55.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$4.08M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+6.4%
Year over year · more shares
Revenue CAGR (3Y)
+9.7%
Revenue CAGR (5Y)
+26.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-281.8%
Debt / equity
0.5
Current ratio
0.7
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.7
Interest coverage
-22.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$1.80M
Latest balance sheet
Cash & equivalents
$2.19M
Total assets
$6.67M
Total debt
$2.08M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$10.32M
Capital expenditures (TTM)
—
R&D (TTM)
$3.26M
SG&A (TTM)
$12.63M
Stock compensation (TTM)
$3.28M
R&D / revenue
79.9%
Stock compensation / revenue
80.3%

Ownership (13F)

9 metrics
13F filers
1
13F filer change QoQ
0
Institutional ownership
0.0%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
0.0%
Active holders' share change QoQ
+0.0%
Holder tenure
26.0
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
9 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 880242 CUSIP 09065A100 Visit website Investor relations